In the post-progression refractory period, inactivation of anti-tumor immunity and resistance to the suppression of tumor signaling by lenvatinib might occur even though VEGF and FGFR signaling were persistently inhibited (Supplementary Fig. 4a, b). The gene discussed is VEGFA; the disease is neoplasm.